Novartis/P&G Enablex Deal Offers OTC Switch Option
This article was originally published in The Tan Sheet
Executive Summary
Procter & Gamble is broadening its long-term Rx-to-OTC switch prospects with a co-promotion deal for Novartis' Enablex (darifenacin) extended-release tablets in the U.S